Biotech Aspirant Hutchmed Sails Full Steam Toward Hong Kong Homecoming IPO
Company backed by billionaire Li Ka-shing secures cornerstone investors for more than half of its $600 million secondary listing in its home market Key points: • Hutchmed announces new approvals…
RELATED ARTICLES
-
AstraZeneca pays hefty price for Chinese weight-loss drug
AZN.US - InSilico seeks IPO boost to get AI drugs over the line
-
BeiGene still bleeding red ink despite blockbuster drug
BGNE.US 6160.HK 688235.SHG
-
Everest reaches new heights on growing drug sales
1952.HK
-
Profit setback for Simcere Pharma in novel drugs quest
2096.HK
